Drug Profile
Y 39983
Alternative Names: RKI-983; SNJ-1656; Y39983Latest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Senju Pharmaceutical
- Class Antiglaucomas; Eye disorder therapies; Pyridines; Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glaucoma
- Discontinued Ocular hypertension
Most Recent Events
- 24 Sep 2021 Discontinued - Phase-II for Ocular hypertension in Japan (Ophthalmic)
- 02 Feb 2018 Y 39983 is still at phase II development stage for Glaucoma and Ocular hypertension in Japan (Ophthalmic) (Senju Pharmaceutical pipeline, February 2018)
- 30 Oct 2008 Phase-II clinical trials in Glaucoma in Japan (Ophthalmic)